Navigation Links
myoscience Announces Robert Grant as Chairman of the Board
Date:1/6/2012

REDWOOD CITY, Calif., Jan. 6, 2012 /PRNewswire/ -- myoscience, Inc. of Redwood City, California is pleased to announce the appointment of Robert E. Grant as Chairman of the Board of Directors effective January 1st, 2012.  Mr. Grant was formerly Chief Executive Officer and President of Bausch & Lomb Surgical and President of Allergan Medical, a division of Allergan.  Mr. Grant has been a board member for myoscience since November 2010 and this latest announcement is a reflection of the company's continuing development as a commercial company in the global aesthetics market.

"We are pleased that Robert has agreed to take the Chairman's role at this important stage of our success.  I have the utmost respect for his strategic talent and his deep understanding of the medical device and pharmaceutical markets," said Clint Carnell, President and Chief Executive Officer of myoscience. "I would also like to thank Rich Ferrari of DeNovo Ventures.  Rich led the Board since its inception and we look forward to his continued contributions as a myoscience board member."

"myoscience's next generation, toxin-free approach to treating nerves for aesthetic and therapeutic applications represents a major advance in neuromodulation. Clint is an adept leader and manager.  He has assembled a talented management team and positioned the company for international commercial launch following recent regulatory approvals in both the EU and Canada," said Mr. Grant. 

About myoscience. myoscience is a privately held medical device company dedicated to developing innovative treatments in whichever fields it chooses to enter. The myoscience technology is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions and focal cryo-treatment of tissue.  The myoscience technology has also been cleared in the US for use in pain management and general surgical use. www.myoscience.com

Contact:
Matt Franklin, 1-650-421-0671  


'/>"/>
SOURCE myoscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Announces Receipt of Notice from Nasdaq
2. Breckenridge Announces Seven Paragraph IV ANDAs in 2011
3. Radient Pharmaceuticals Announces New Advertisement for Oncology Publications
4. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
5. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
6. Cascade Medical Enterprises, LLC Announces the Sale of Their Orthopedic Business
7. Tris Pharma Announces US Patent Grant Covering Platform Technology
8. BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
9. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
10. Acella Pharmaceuticals, LLC Announces Its Acquisition of the PRENATE® Family of Trademarks and Associated Intellectual Property
11. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ... Joseph R. Goodwin , U.S. District Court Judge ... , entered a case management order in MDL ... Liability Litigation (the "MDL") that includes a provision requiring ... disclosures on specific causation within one hundred twenty (120) ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... 28, 2017 , ... Guide to FDA and EU Medical Device Regulations: 2017 ... side of the Atlantic devicemakers do business, this fully updated and expanded guide keeps ... addition to the full text of the FDA’s regulations in 21 CFR Parts 800 ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... David B. Sosin, a founding ... Illinois, took over the post of 2nd Vice President for the Illinois State Bar ... installed as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served ...
(Date:6/28/2017)... Columbia (PRWEB) , ... June 28, 2017 , ... ... (FSE: ZEON) is pleased to announce that a two year study conducted by ... Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... ... 2017 , ... Harbour , a DAO (decentralized autonomous organization) that harnesses ... released their technical specifications . , 2017 has seen an explosion of token ... determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of ...
Breaking Medicine News(10 mins):